Document Detail


Medically refractory neurosarcoidosis treated with infliximab.
MedLine Citation:
PMID:  21507165     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Neurosarcoidosis can worsen despite standard immunosuppressive therapy, a situation for which there is no established medical management. We present three cases of medically refractory neurosarcoidosis treated with infliximab. All three patients showed a clinical response to this treatment and side effects were limited. A summary of reported cases of neurosarcoidosis treated with infliximab is included. This case series supports a role for infliximab in the treatment of patients with medically refractory neurosarcoidosis.
Authors:
J Pereira; N E Anderson; D McAuley; P Bergin; D Kilfoyle; J Fink
Related Documents :
21426375 - Factors associated with dropout in medical education: a literature review.
21514485 - Policy implications of oral agents.
21545445 - An interactional approach to conceptualising small talk in medical interactions.
21518115 - Medication errors--new approaches to prevention.
17005045 - Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical in...
1120755 - Maximal aerobic capacity at different levels of carboxyhemoglobin.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Internal medicine journal     Volume:  41     ISSN:  1445-5994     ISO Abbreviation:  Intern Med J     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-21     Completed Date:  2012-03-06     Revised Date:  2012-03-29    
Medline Journal Info:
Nlm Unique ID:  101092952     Medline TA:  Intern Med J     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  354-7     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.
Affiliation:
Department of Medicine, University of Auckland Department of Neurology, Auckland City Hospital, Auckland, New Zealand. j.pereira@auckland.ac.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal / administration & dosage*
Central Nervous System Diseases / diagnosis*,  drug therapy*,  immunology
Drug Administration Schedule
Drug Resistance / drug effects,  immunology
Female
Follow-Up Studies
Humans
Immunosuppressive Agents / administration & dosage
Male
Sarcoidosis / diagnosis*,  drug therapy*,  immunology
Treatment Outcome
Tumor Necrosis Factor-alpha* / immunology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab
Comments/Corrections
Comment In:
Intern Med J. 2012 Feb;42(2):232   [PMID:  22356508 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevalence and molecular study of G6PD deficiency in Malaysian Orang Asli.
Next Document:  Blood transfusion: old blood, new blood or no blood.